<DOC>
	<DOCNO>NCT02594176</DOCNO>
	<brief_summary>Primary Objective To substantiate efficacy 2.2 g FLEXISEQ® treatment pain related osteoarthritis ( OA ) knee patient contraindicate clinical intolerance NSAIDs . Secondary Objectives - To substantiate efficacy 2.2 g FLEXISEQ® treatment stiffness improvement joint function patient contraindicate clinical intolerance NSAIDs OA knee . - To substantiate safety tolerability 2.2 g FLEXISEQ® patient contraindicate clinical intolerance NSAIDs OA knee .</brief_summary>
	<brief_title>Study FLEXISEQ® Treatment Osteoarthritis Knee NSAID-compromised Patients</brief_title>
	<detailed_description>This post marketing clinical follow-up , randomise , double-blind study compare efficacy tolerability topical FLEXISEQ® placebo treatment osteoarthritis knee patient contraindicate clinical intolerance NSAIDs OA knee total individual treatment period 12 week .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>1 . Signed date informed consent prior studymandated procedure 2 . Willing able comply study requirement 3 . Outpatients age ≥ 50 ( start day 50th birthday ) 4 . Patient knee pain bad pain body able identify predominantly painful ( target ) knee 5 . Patient primary diagnosis Functional Class IIII OA target knee patient meet American College Rheumatology ( ACR ) clinical classification criterion osteoarthritis knee 6 . NSAID contraindicate clinically intolerant 7 . Females able conceive ( include perimenopausal woman menstrual period within 1 year ) must use appropriate birth control ( define method result low failure rate 8 . If female able conceive , patient negative urine pregnancy test screen General exclusion criterion 1 . Planned treatment treatment another investigational drug within 30 day prior randomisation 2 . Patients inmates psychiatric ward , prison , state institution 3 . Investigator team member involve directly indirectly conduct clinical study 4 . Pregnancy lactation 5 . Any planned expect hospitalisation within study period 6 . Patients able perform WOMAC test ( physically handicap immobile patient , e.g . wheelchair bound ) 7 . Any health condition , investigator 's opinion mean patient likely unable complete 12 week study Medical history relate exclusion criterion 8 . Skin lesion dermatological disease treatment area 9 . Extreme obesity ( BMI &gt; 35 ) 10 . Uncontrolled hypertension 11 . Requiring dialysis 12 . Hepatocellular insufficiency prevent use paracetamol 13 . Alcohol abuse 14 . Intolerance paracetamol 15 . Malignancy within past 2 year 16 . Morbus Meulengracht/Gilbert Syndrome 17 . Neurological psychiatric disorder compromise pain rating patient , limited depressive disorder , schizophrenia epilepsy 18 . Any pain condition require acute chronic use pain medication discontinue screen 19 . Inflammatory arthritis include rheumatoid arthritis , psoriatic arthritis , gout , pseudo gout , systemic lupus erythematodes , ankylose spondylitis , mixed connective tissue disease 20 . Symptomatic hip OA ipsilateral target knee 21 . Severe ( axial misalignment &gt; 10° ) , uncorrected genu vara genu valga 22 . Arthroscopy target knee within 6 month prior study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Pain</keyword>
	<keyword>NSAID</keyword>
	<keyword>Sequessome</keyword>
</DOC>